SCHEMBL13879683

SCHEMBL13879683

COC(=O)c1cccc(NC(=O)/C=C/c2ccc(Sc3ccc(F)cc3)cc2C(F)(F)F)c1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAOB P27338 5/20 0.53
MAPT P10636 9/20 0.47
MEN1 O00255 5/20 0.47
KMT2A Q03164 5/20 0.47
LMNA P02545 4/20 0.47
ALDH1A1 P00352 4/20 0.46
MAPK1 P28482 2/20 0.46
RAB9A P51151 4/20 0.46
CYP1A2 P05177 1/20 0.46
CYP3A4 P08684 1/20 0.46
CYP2C19 P33261 1/20 0.46
SMN1; SMN2 Q16637 6/20 0.46
NPC1 O15118 3/20 0.46
KDM4E B2RXH2 2/20 0.45
HIF1A Q16665 2/20 0.44
MAOA P21397 1/20 0.43
MMP1 P03956 1/20 0.41
MMP2 P08253 1/20 0.41
MMP9 P14780 1/20 0.41
TP53 P04637 2/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4280129 0.87 MAPT (0.51) MAOBMAPTMEN1KMT2ALMNA
SCHEMBL4280130 0.87 MAPT (0.51) MAOBMAPTMEN1KMT2ALMNA
SCHEMBL13879594 0.80 MAPT (0.48) MAPTMEN1KMT2ALMNAALDH1A1
SCHEMBL4277201 0.76 MAPT (0.49) MAOBMAPTMEN1KMT2ALMNA
SCHEMBL4277198 0.76 MAPT (0.49) MAOBMAPTMEN1KMT2ALMNA
SCHEMBL13879679 0.73 SMN1; SMN2 (0.41) MAOBMAPTMEN1KMT2ALMNA
SCHEMBL13879684 0.72 MAOB (0.39) MAOBMAPTMEN1KMT2ALMNA
SCHEMBL13879687 0.71 MAOB (0.40) MAOBMAPTMEN1KMT2ALMNA
SCHEMBL13879685 0.71 SMN1; SMN2 (0.41) MAOBMAPTMEN1KMT2ALMNA
SCHEMBL8060458 0.70 MAOB (0.76) MAOBMAPTMEN1KMT2ALMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090099186-A1 INHIBITORS OF VIRAL REPLICATION INTERMUNE, INC. 2009-04-16 US disclosed
US-20090099186-A1 INHIBITORS OF VIRAL REPLICATION INTERMUNE, INC. 2009-04-16 US disclosed
WO-2007047146-A2 INHIBITORS OF VIRAL REPLICATION INTERMUNE, INC. (US) 2007-04-26 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090099186-A1 INHIBITORS OF VIRAL REPLICATION EIF2AK2, HAVCR2, RTF2 MAOB 2266/4885MAPT 4203/4885MEN1 4395/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.